Artificial Pancreas Device System Market Research Report–Forecast till 2027

Artificial Pancreas Device System Market Research Report by Type (CTR, CTT), End-user (Hospitals, Medical Centers, and Others), and Region (North America, Europe, APAC, RoW)- Forecast to 2027

ID: MRFR/MED/5208-HCR | February 2021 | Region: Global | 100 pages         

Artificial Pancreas Device System Market

Artificial Pancreas Device System Market is expected to reach USD 556.8 Million at CAGR of 21.3% during the forecast period of 2022-2030

Segmentation

By Type CTR (Control to Range) Systems CTT (Control To Target) Systems
By End Users Hospitals Medical Centers

Key Players

  • Medtronic Plc
  • Bigfoot Biomedical
  • Johnson & Johnson
  • Dexcom Inc.
  • Cellnovo
  • Tandem Diabetes Care Inc.
  • Pancreum Inc.
  • TypeZero Technologies LLC
  • Beta Bionics
  • F. Hoffmann-La Roche Ltd
  • Inreda Diabetic B.V.
  • nsulet Corp

Drivers

  • Number of cases being diagnosed with diabetes
  • Rising inflow of investment
Speak to Analyst Request a Free Sample

Artificial Pancreas Device System Market Snapshot


The demand for artificial pancreas devices has increased lately as the cases related to pancreatic ailments and failures have grown substantially. The market is set to attain revenues valued at USD 341.08 million while forging ahead at a CAGR of 21.10% in the upcoming forecast period between 2017 and 2023. The escalating number of cases being diagnosed with diabetes is the key factor in promoting the development of the market. The rising inflow of investment in the market is expected to improve the product quality, thus increasing the sales of the market. As patients these days are more or less aware of the treatment options, they are also increasingly involved in the selection of their treatment options in certain cases. This factor is anticipated to reflect positively in the expansion of the artificial pancreas device system market in the upcoming forecast period.


Report Overview


The market perspective offered by MRFR spans the entire market and gives in-depth coverage of the latest trends that are shaping the future of the artificial pancreas device system market. The report aptly captures the development of the market through current market trends, historical growth analysis, and revenue projections for a period ranging to 2023. The market also mentions CTR (Control to Range) Systems and CTT (Control to Target) Systems. The end user segments such as hospital and medical centers are also significantly emphasized upon, and a detailed analysis of the segments is also presented in the report. The market dynamics related to pricing and feasibility analysis is significantly along with macroeconomic indicators, and feasibility indicators provides a comprehensive overview of the artificial pancreas device system market in the forecast period.


Report Coverage


The report on the artificial pancreas device system market consists of market dynamics, forecast, historical market trends, market value by region as well as by country-level analysis for each market segment, segmentation, market factor analysis and key player’s market share analysis that includes supply chain and Porter’s five forces analysis of the market.


Companies Covered


Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp


Research Methodology


The progression of research while creating reports at Market Research Future includes highlights and facts that are essential to the expansion of artificial pancreas device system market. The research initiated by our analysts enhances the capability of our clients to outline their vision for growth better. The unification of primary and secondary research approaches in our reports divulges widespread information connected to new revenue pockets and developing markets globally. The report methodology also ensures strategy roadmaps that exhibit a distinct picture of the present trends as well as the trends that can affect the forthcoming development of the artificial pancreas device system market. An intrinsic level of understanding connected to the value chain in a specific market additionally contributes to the value of the reports created by our analysts. Furthermore, the insights into markets, technologies, and industry sectors is positively achieved by the application of top-down and bottom-up approaches.


Segmental Analysis


The segmentation of the artificial pancreas device market has been carried out to better gauge the artificial pancreas device system market.


By Type



  • CTR (Control to Range) Systems

  • CTT (Control To Target) Systems


By End User



  • Hospitals

  • Medical Centers


By Region



  • North America

  • South America

  • Europe

  • Asia-Pacific

  • Middle East

  • Africa



Report Scope:
Report Attribute/Metric Details
  Market Size   2023: 341.08 million
  CAGR   2018-2023: 21.10%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, End User and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp
  Key Market Opportunities   Product Manufacturer
  Key Market Drivers

  • Number of cases being diagnosed with diabetes
  • Rising inflow of investment


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The types are included in the artificial pancreas device system market are CTR (Control to Range) Systems, CTT (Control To Target) Systems.

    The major drivers of artificial pancreas device system market are Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp.

    Artificial Pancreas Device System Market is expected to reach US 341.08 million and at a CAGR 21.10% through 2023.

    The Major driving factor of Artificial Pancreas Device System Market is Number of cases being diagnosed with diabetes.